Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients

Early VEGF-A reduction (EVR) by targeting abundant VEGF-A is a potential predictive marker of bevacizumab (BEV). The CCL5/ CCR5 axis modulates VEGF-A production via endothelial progenitor cells migration. We tested whether genetic polymorphisms in the CCL5/CCR5 pathway could predict efficacy of BEV...

詳細記述

保存先:
書誌詳細
出版年:Int J Cancer
主要な著者: Suenaga, Mitsukuni, Cao, Shu, Zhang, Wu, Yang, Dongyun, Ning, Yan, Okazaki, Satoshi, Berger, Martin D., Miyamoto, Yuji, Schirripa, Marta, Soni, Shivani, Barzi, Afsaneh, Yamaguchi, Toshiharu, Lenz, Heinz-Josef
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497849/
https://ncbi.nlm.nih.gov/pubmed/30411783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31968
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料